|
1
|
Yamanaka R, Abe T, Yajima N, Tsuchiya N,
Homma J, Kobayashi T, Narita M, Takahashi M and Tanaka R:
Vaccination of recurrent glioma patients with tumour lysate-pulsed
dendritic cells elicits immune responses: Results of a clinical
phase I/II trial. Br J Cancer. 89:1172–1179. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu JS, Liu G, Ying H, Yong WH, Black KL
and Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic
cells elicits antigen-specific, cytotoxic T-cells in patients with
malignant glioma. Cancer Res. 64:4973–4979. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liau LM, Prins RM, Kiertscher SM, Odesa
SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS,
Cloughesy TF and Roth MD: Dendritic cell vaccination in
glioblastoma patients induces systemic and intracranial T-cell
responses modulated by the local central nervous system tumor
microenvironment. Clin Cancer Res. 11:5515–5525. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valle RD, de Cerio AL, Inoges S, Tejada S,
Pastor F, Villanueva H, Gallego J, Espinos J, Aristu J, Idoate MA,
et al: Dendritic cell vaccination in glioblastoma after
fluorescence-guided resection. World J Clin Oncol. 3:142–149. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fabry Z, Raine CS and Hart MN: Nervous
tissue as an immune compartment: The dialect of the immune response
in the CNS. Immunol Today. 15:218–224. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carmen J, Gowing G, Julien JP and Kerr D:
Altered immune response to CNS viral infection in mice with a
conditional knock-down of macrophage-lineage cells. Glia. 54:71–80.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Andersson U and Tracey KJ: Neural reflexes
in inflammation and immunity. J Exp Med. 209:1057–1068. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palucka K and Banchereau J: Cancer
immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Almolda B, Costa M, Montoya M, Gonzàlez B
and Castellano B: Increase in Th17 and T-reg lymphocytes and
decrease of IL22 correlate with the recovery phase of acute EAE in
rat. PloS One. 6:e274732011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng F, Guo Z, Xu H, Yan D and Li Q:
Decreased plasma IL22 levels, but not increased IL17 and IL23
levels, correlate with disease activity in patients with systemic
lupus erythematosus. Ann Rheum Dis. 68:604–606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Belle AB, de Heusch M, Lemaire MM,
Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld
JC and Dumoutier L: IL-22 is required for imiquimod-induced
psoriasiform skin inflammation in mice. J Immunol. 188:462–469.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao
Y, Wang X and Sun B: Interleukin-22 promotes human hepatocellular
carcinoma by activation of STAT3. Hepatology. 54:900–909. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lejeune D, Dumoutier L, Constantinescu S,
Kruijer W, Schuringa JJ and Renauld JC: Interleukin-22 (IL-22)
activates the JAK/STAT, ERK, JNK and p38 MAP kinase pathways in a
rat hepatoma cell line. Pathways that are shared with and distinct
from IL-10. J Biol Chem. 277:33676–33682. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang W, Chen Y, Wei H, Zheng C, Sun R,
Zhang J and Tian Z: Antiapoptotic activity of autocrine
interleukin-22 and therapeutic effects of interleukin-22-small
interfering RNA on human lung cancer xenografts. Clin Cancer Res.
14:6432–6439. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sabat R, Ouyang W and Wolk K: Therapeutic
opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov.
13:21–38. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kreymborg K, Etzensperger R, Dumoutier L,
Haak S, Rebollo A, Buch T, Heppner FL, Renauld JC and Becher B:
IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but
not required for the development of autoimmune encephalomyelitis. J
Immunol. 179:8098–8104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Backert I, Koralov SB, Wirtz S, Kitowski
V, Billmeier U, Martini E, Hofmann K, Hildner K, Wittkopf N, Brecht
K, et al: STAT3 activation in Th17 and Th22 cells controls
IL-22-mediated epithelial host defense during infectious colitis. J
Immunol. 193:3779–3791. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davis FG and McCarthy BJ: Current
epidemiological trends and surveillance issues in brain tumors.
Expert Rev Anticancer Ther. 1:395–401. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Colleoni F and Torrente Y: The new
challenge of stem cell: Brain tumour therapy. Cancer Lett.
272:1–11. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Silber J, Lim DA, Petritsch C, Persson AI,
Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello
JF, et al: miR-124 and miR-137 inhibit proliferation of
glioblastoma multiforme cells and induce differentiation of brain
tumor stem cells. BMC Med. 6:142008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei J, Wang F, Kong LY, Xu S, Doucette T,
Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, et al: MiR-124
inhibits STAT3 signaling to enhance T cell-mediated immune
clearance of glioma. Cancer Res. 73:3913–3926. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaplan MH, Schindler U, Smiley ST and
Grusby MJ: Stat6 is required for mediating responses to IL-4 and
for development of Th2 cells. Immunity. 4:313–319. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Monteleone G, Holloway J, Salvati VM,
Pender SL, Fairclough PD, Croft N and MacDonald TT: Activated STAT4
and a functional role for IL-12 in human Peyer's patches. J
Immunol. 170:300–307. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morinobu A, Gadina M, Strober W, Visconti
R, Fornace A, Montagna C, Feldman GM, Nishikomori R and O'Shea JJ:
STAT4 serine phosphorylation is critical for IL-12-induced
IFN-gamma production but not for cell proliferation. Proc Natl Acad
Sci USA. 99:12281–12286. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sovran B, Loonen LM, Lu P, Hugenholtz F,
Belzer C, Stolte EH, Boekschoten MV, van Baarlen P, Kleerebezem M,
de Vos P, et al: IL-22-STAT3 pathway plays a key role in the
maintenance of ileal homeostasis in mice lacking secreted mucus
barrier. Inflamm Bowel Dis. 21:531–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Liu W, Alizadeh D, Zhao D,
Farrukh O, Lin J, Badie SA and Badie B: S100B attenuates microglia
activation in gliomas: Possible role of STAT3 pathway. Glia.
59:486–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lo HW, Cao X, Zhu H and Ali-Osman F:
Constitutively activated STAT3 frequently coexpresses with
epidermal growth factor receptor in high-grade gliomas and
targeting STAT3 sensitizes them to Iressa and alkylators. Clin
Cancer Res. 14:6042–6054. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zisakis A, Piperi C, Themistocleous MS,
Korkolopoulou P, Boviatsis EI, Sakas DE, Patsouris E, Lea RW and
Kalofoutis A: Comparative analysis of peripheral and localised
cytokine secretion in glioblastoma patients. Cytokine. 39:99–105.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suzumura A, Sawada M, Yamamoto H and
Marunouchi T: Transforming growth factor-beta suppresses activation
and proliferation of microglia in vitro. J Immunol. 151:2150–2158.
1993.PubMed/NCBI
|
